The information in this section is intended for visitors outside the United States.
Gilead Sciences Announces Changes to Senior Management Team
Gilead Sciences Announces Termination of Its U.S. Development Program for Adefovir Dipivoxil for HIV
Gilead Begins Multinational Phase III Trial of Once Daily Oral Anti-HIV Drug, Tenofovir Disoproxil Fumarate
Roche Announces New Data on Recently Approved Tamiflu™, First Pill to Treat the Most Common Strains of Influenza (A & B)
Gilead Sciences Announces Results of FDA Advisory Panel on Anti-HIV Agent, Adefovir Dipivoxil 60 Mg
Roche Receives FDA Approval Of TAMIFLU™, First Pill To Treat The Most Common Strains Of Influenza (A&B)
Gilead Announces Third Quarter 1999 Financial Results
1999 Third Quarter Highlights
Gilead Sciences Completes European Marketing Authorisation Application For Anti-HIV Agent Adefovir Dipivoxil 60 Mg
Gilead Sciences Amends Stockholder Rights Plan
AmBisome® Phase III Study For Cryptococcal Meningitis
Preliminary Phase II Clinical Results For Once-Daily Anti-HIV Agent, Tenofovir DF, Presented At ICAAC
First Approval of Roche’s Tamiflu™, a New Flu Treatment
Gilead Sciences Announces Acceptance Of Late Breaker Abstract At Upcoming Scientific Conference
Gilead Acquisition Of NeXstar Completed
Gilead Announces Second Quarter 1999 Financial Results
Gilead Sciences and NeXstar Pharmaceuticals Announce Date for Special Stockholders Meetings to Approve Merger
Hoffmann-La Roche Submits New Drug Application to Market New Flu Pill
Gilead Announces First Quarter 1999 Financial Results
Gilead Presents Preliminary Clinical Data Demonstrating Activity of Adefovir Dipivoxil Against Lamivudine-Resistant Hepatitis B Virus
Gilead Begins Multinational Phase III Trial of Hepatitis B Drug, Adefovir Dipivoxil
Gilead Sciences and NeXstar Pharmaceuticals to Merge
Gilead Announces Fourth Quarter and 1998 Year-End Financial Results